Hair Transplant for Men: Full Guide, Cost & Recovery Tips
1. Why Do Men Lose Hair?
Hair loss in men is most commonly due to androgenetic alopecia (male pattern baldness), a hereditary condition linked to hormones like DHT. Other causes include:
Stress or trauma
Poor diet or malnutrition
Medical conditions (thyroid, anemia)
Certain medications
Scalp infections
Excessive hairstyling or heat damage
2. Types of Hair Transplant Procedures
a. FUE (Follicular Unit Extraction)
Individual hair follicles are extracted from the donor area and implanted into the thinning or balding area.
Minimally invasive, no stitches.
Leaves tiny dot scars, almost invisible.
Popular for men who prefer short haircuts.
b. FUT (Follicular Unit Transplantation / Strip Method)
A strip of scalp is removed from the donor area, and follicles are dissected and transplanted.
Leaves a linear scar on the donor site.
Slightly more grafts can be extracted in one session.
Often cheaper than FUE.
c. DHI (Direct Hair Implantation)
A more advanced variation of FUE using a pen-like tool to directly implant follicles.
Often more precise but more expensive.
3. Duration of the Procedure
4. Recovery Timeline & When You Can Go Out
5. Side Effects & Risks
Swelling (forehead/eyes for 2–3 days)
Scabbing & itching
Shock loss (temporary shedding of transplanted or existing hair)
Redness and inflammation
Numbness or tingling in donor area
Infection or cysts (rare)
6. How to Minimize Side Effects
Follow all post-op instructions from your surgeon
Sleep with head elevated for 3–5 days
Avoid exercise, swimming, or sweating for 10–14 days
Don't scratch or pick scabs
Use prescribed antibiotic shampoo and medication
Avoid sun exposure for 2–3 weeks
No smoking or alcohol for 1 week pre/post surgery
7. Hair Transplant Cost
Cost varies by country, clinic reputation, technique, and number of grafts:
Most clinics charge per graft: $1–$5/graft.
8. Patient Satisfaction & Results
Most men report high satisfaction rates —typically 85–90%—if:
The procedure is done by an experienced, licensed surgeon
Post-op care is followed diligently
Expectations are realistic (you may need a second session)
The hair density and donor area are sufficient
Common feedback includes:
👍 "Natural-looking hairline"
💬 "I look 10 years younger"
💡 "Best investment in my confidence"
Should You Do a Hair Transplant?
Hair transplants are more advanced and effective than ever. Whether you're struggling with hair thinning or bald patches, a transplant can offer long-term, natural results —but only if you do your research, choose a reputable clinic, and stick to the recovery plan.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
UAE Moments
2 hours ago
- UAE Moments
Daily Affirmation for July 27, 2025 to Kickstart Your Vibe
✨ Today's Affirmation: "I trust the timing of my life and welcome every new beginning with an open heart." ? Vibe Check: Feeling a little restless? Like you're stuck in that weird in-between of wanting more but not sure how or when it's coming? Totally normal. Today's cosmic whisper: Trust that everything is unfolding even when it feels like you're standing still. You're not behind. You're exactly on time. Why This Works: When you're craving change, it's tempting to force things to happen ASAP. But growth — real, soul-deep growth — is more like a sunrise than a light switch. This affirmation reminds you that patience is progress, and your heart knows the way. Your Mini Mission: Ease into trust today with these tiny steps: – Write down three small wins you've had in the past month (they count, even if they feel tiny). – Practice saying out loud: 'I am on my own timeline, and that's enough.' – Pause before rushing a decision — give yourself permission to feel ready before moving forward. Power Up Playlist: Songs for trusting your glow-up season: 'Good as Hell' – Lizzo 'Hold On' – Wilson Phillips 'Shake It Out' – Florence + The Machine 'Dog Days Are Over' – Florence + The Machine 'Brave' – Sara Bareilles Bonus Energy Tip: Wear or carry a piece of moonstone today. Moonstone is the ultimate "trust the process" stone — it encourages intuition, patience, and flow. Whenever you feel anxious about the future, touch it and repeat: "New beginnings are always on my side."
The National
15 hours ago
- The National
From beauty to gaming: How smart tech is quietly transforming accessibility
More than 1.3 billion people globally – about 16 per cent of the world's population – live with some form of disability, according to the World Health Organisation. That includes a broad range of physical, sensory, cognitive and age-related conditions. Among them, millions live with limited mobility or fine motor challenges, impairments that can make routine tasks like styling hair, applying make-up, or playing video games significantly more difficult. Innovative consumer technology is now helping people with disabilities gain more independence, confidence and control, often without being explicitly marketed as assistive. Tools from Dyson, L'Oréal, and Microsoft are leading a shift towards inclusive design, proving that innovation for the mainstream can also empower those at the margins. 'It's not about whether I can do something – it's about whether a product allows me to do it efficiently, independently and with the same experience as everyone else,' Jessica Smith, a disability advocate born without a left forearm, tells The National. An empowering styling tool Ms Smith has been using the new Dyson Airwrap i.d., a hair styling tool that uses sensors, airflow control and app-based settings to simplify the process of curling and drying hair. She says it's one of the few beauty tools that feels like it was made with people like her in mind. 'The ability to style hair with one hand more seamlessly is a game-changer,' she adds. 'It's exciting to see how it can support my routine.' According to Dyson, the product's accessibility benefits weren't part of the original design brief but emerged organically through efforts to make styling easier for all users. 'The brief was always to make styling and curling hair more convenient and easier for everyone, not necessarily catering to users with disabilities,' Low Chen Nyeow, associate design manager at Dyson Beauty, tells The National. The Airwrap i.d. connects to an app that automates different steps in the styling process, which is helpful for people with limited mobility. 'It removes the need for them to continually press the power button during the styling process as well as hold the cool shot button down,' Ms Nyeow said. In addition, the device's self-wrapping barrels and personalised presets cut manual efforts by users. 'Hair gets wrapped automatically, even without the user feeding a hair tress to the barrel,' she added. 'The personalised curling sequence simplifies usage and allows users to tailor their styling experience without needing to hold multiple buttons down.' Ms Smith said she hopes more companies follow Dyson's example, even if inclusivity isn't their starting point. 'Inclusion should be the standard, not an afterthought,' she says. 'Beauty and personal care are a huge part of people's confidence and self-expression, but for too long, brands have overlooked the needs of disabled consumers. That's how innovation truly meets our needs.' At Dyson, accessibility remains a vital area of continuing research. 'Although we do not have immediate plans to integrate voice or gesture controls into beauty tools, our research teams are investigating how emerging technologies could be incorporated in the future,' Ms Nyeow says. Growing market with untapped potential Assistive technology is a rapidly growing sector focused on enhancing the quality of life for people with disabilities or age-related limitations. It includes products, devices, and software that support users in performing everyday tasks, from communication and mobility to personal care and digital access. The global assistive technology market is projected to reach $41 billion by 2033, from $26.8 billion in 2024, according to market research company Imarc Group. Much of this growth comes from specialised companies focused on health care, mobility, and communication. For example, Sweden's Tobii Dynavox Global develops eye-tracking and speech-generating devices for people with neurological conditions. The US company Ekso Bionics develops wearable exoskeletons that enable individuals with paralysis or mobility impairments to walk again. Aira Technologies is another innovator, offering real-time visual assistance through smart glasses for people who are blind or visually impaired. Mainstream brands like Dyson, L'Oréal, and Microsoft are contributing to the space. Their consumer-first innovations, while not always designed with disability in mind, are proving to be inclusive by default, showing that accessible design can have the most significant impact when it's built for everyone. Innovative make up L'Oréal's HAPTA, an innovative lipstick applicator for people with limited hand or arm mobility, is an example. With its launch in January 2023 at the Consumer Electronics Show (CES) in Las Vegas, L'Oréal put inclusive design at the centre of innovation. The device uses sensors and gyroscopic technology to stabilise motion, helping users apply make-up without requiring a full range of movement. According to a company statement, HAPTA was developed to meet the needs of an estimated 50 million people worldwide who live with limited motor skills. This condition can make daily tasks, such as applying make-up, especially difficult. The hand-held applicator incorporates technology initially developed by Verily to stabilise utensils for people with mobility impairments, now adapted to beauty routines. 'Inclusivity is at the heart of our innovation and beauty tech strategy,' Barbara Lavernos, the company's deputy chief executive in charge of research, innovation, and technology said in a statement at the launch. HAPTA features customisable attachments and built-in smart motion controls to increase range of motion and ease of use. It features a magnetic rotating head that provides 360 degrees of rotation and 180 degrees of flexion, enabling users to save preferred positions for future use. 'With HAPTA, we are going one step further by making beauty more accessible to use because everyone should have equal access to it,' Françoise Lehmann, Lancôme global brand president, said at the time. Gaming for all In the gaming world, Microsoft's Xbox Adaptive Controller has become a leading example of how mainstream tech can deliver powerful accessibility. Designed for players with limited mobility, the device features oversized buttons and multiple input ports that connect to custom accessories, including foot pedals, switches, and sip-and-puff systems. These features enable users to personalise their gaming experience according to their physical needs. 'The goal of the Xbox Adaptive Controller is to remove that barrier. We strive to make Xbox the most accessible gaming platform on the market,' Microsoft said in its fact sheet on the device. 'The Xbox Adaptive Controller provides a much-needed, simple, and affordable solution for gamers with limited mobility.'
Zawya
4 days ago
- Zawya
Five years after COVID, pharma shares languish in US policy limbo
MILAN - Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies' earnings outlook is being obscured by concerns over revived "most-favored-nation" drug pricing rules in the lucrative U.S. market and potential 200% tariffs on pharma imports into the U.S. Money flooded into drugmakers' shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the sector cheap but unloved. At 15.9 times forward earnings, healthcare trades 11% below its long-term average and 20% below global equities, its steepest discount in 16 years, just above a record discount in 2009, based on LSEG Datastream data. "We've moved from cautious optimism to cautious pessimism," said Stephanie Aliaga, global market strategist at J.P. Morgan Asset Management in New York. "Valuations have gotten even cheaper, but for a reason," she added, referring to intensifying U.S. policy risks. But some investors are starting to look past the Washington policy fog and at long-term positive drivers, such as aging populations, RNA-based therapeutics, and breakthroughs in weight-loss and diabetes drugs. 'ARMAGEDDON SCENARIO' Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts boosting this rate-sensitive sector. Interest rate cuts typically support healthcare by lowering R&D funding costs and boosting the value of future cash flows. "These are quality companies with good growth and defensive features being priced as if we're heading into an 'Armageddon scenario', which I believe is unlikely," he said. UK-based M&G Investments has also been selectively adding to healthcare, according to its latest allocation report. Healthcare funds have seen net inflows since 2024, more than reversing the outflows from late 2022 through 2023, fund tracker EPFR data shows. Although year-to-date, inflows total $7.2 billion, down 41% from last year. Innovation is accelerating, pipelines are maturing and M&A is showing signs of picking up - yet stock prices are unmoved. Whether that represents a buying opportunity or a value trap hinges on how and when the policy uncertainty clears, investors said. CATALYST NEEDED Historically, healthcare has traded at a modest premium to world stocks, thanks to its defensive profile and steady earnings. But that narrative has unravelled under political pressure from Washington and investors' love of Big Tech. Over the past three years, U.S. healthcare has underperformed the S&P 500 by more than 60 percentage points, making it the worst sectoral performer on Wall Street. Its valuation has deepened to a near-record 27% discount, from parity to the S&P in 2023. "Markets don't like uncertainty, and that shows up in valuations," said Eddie Yoon, healthcare sector leader and portfolio manager at Fidelity Investments in Boston. "Being cheap isn't necessarily a reason to buy. You need a catalyst." For now, that catalyst is elusive. The policy uncertainty makes it difficult to forecast future earnings, he said, though he hopes for more clarity by year-end - potentially also paving the way for more M&A in the industry. Talks with the Trump administration have yet to clarify how and when drug prices will fall, executives from Eli Lilly and Merck said at a May industry conference. Yoon, who has typically been underweight Big Pharma due to patent expiry risks, notes smaller, innovative firms are becoming profitable. "We're seeing companies go from unprofitable to very profitable," he said, citing Alnylam and Penumbra as examples he owns. "Historically, that's been a very good time to own healthcare stocks." LFG+ZEST's Conca, who favours U.S. names like Abbott , Edwards Lifesciences, and AbbVie, along with Sanofi and Recordati in Europe, said interest rate cuts could be a major catalyst. OUT OF THE WOODS? In Europe, healthcare is even cheaper than U.S. pharma, trading at 14.3 times forward earnings. A 55% drop in shares of Novo Nordisk in the last year, related in part to concerns over competition in obesity drugs, along with tariff-driven production shifts to the U.S., has weighed on valuations. "The sector will adapt," wrote Arnaud Cadart, healthcare analyst at France's CIC Market Solutions. But that will come "at the cost of rebalancing its revenues and probably transforming its organisations." AstraZeneca, for example, has unveiled a $50 billion U.S. investment. For now, the sector remains in limbo: cheap, but lacking enough visibility to trigger a broad re-rating. "Healthcare has endured a lot of pain," said J.P. Morgan's Aliaga. "We're not sure if that pain is done, but the worst is likely over, given how extreme the exodus has been." (Reporting by Danilo Masoni; Editing by Amanda Cooper and Jane Merriman)
